Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
Views & Analysis Nine for 2019: Challenges impacting pharma As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
